Lupin Receives U.S. FDA Approval for Amifampridine Tablets

What happened

Lupin announced that the U.S. Food and Drug Administration approved its application for Amifampridine Tablets, 10 mg, which the company says are equivalent to Firdapse for the approved labeling. Lupin says it is among the first applicants and eligible for 180 days of shared generic exclusivity.

Confirmed

Global impact / market context

Approval allows Lupin to sell a generic version for the approved use, while shared exclusivity may limit how many other generic sellers enter during the stated period. That could bring sales to Lupin and increase price competition for the reference drug, though the article gives no launch date or revenue estimate.

Analyst inference

The announcement concerns one medicine, not Lupin’s wider portfolio. Its commercial effect depends on when sales begin, demand, and the number of eligible generic competitors. Because exclusivity is shared, Lupin’s potential advantage is not an exclusive 180-day period alone.

Analyst inference

What to watch

1. Watch for Lupin to announce when U.S. sales begin; the approval itself does not state a launch date, and timing determines when the product can contribute revenue. Analyst inference
2. Check how many other companies qualify for shared generic exclusivity, since more sellers during the 180-day period could divide demand and increase competition. Analyst inference
3. Look for company updates on sales or financial results from Amifampridine Tablets; the announcement provides no forecast for revenue, pricing, or profit per sale. Analyst inference

Evidence

• Original source link unavailable